ArticleNature communications2023
A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Sustained Delivery of a Shingles Subunit Vaccine Overcomes Age-Related Declines in Humoral and Cellular Immunity Relative to Shingrix.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Virus glycoprotein nanodisc platform for vaccine analytics.Nature communications · 2026Article
- Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency.PloS one · 2026Article
- Fever Inspiration: Precision Engineering for Safe and Systemic Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Article
- Biomimetic carbon nanopolymers ANM-NPs act on mannose receptors and complement receptors to promote tumor antigen presentation.Journal for immunotherapy of cancer · 2025Article
- Article
- Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights.Pharmaceutics · 2025Review
- Early, adjuvant-responsive epigenetic programs in B cells imprint subsequent plasma cell survival and the duration of humoral immunity.bioRxiv : the preprint server for biology · 2025Article
- Vaccination with an mRNA-encoded membrane-bound HIV envelope trimer induces neutralizing antibodies in animal models.Science translational medicine · 2025Article
- Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion.Science translational medicine · 2025Article
- The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates.The Journal of clinical investigation · 2025Article
- Article
- Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.Pharmaceutics · 2025Review
- Modulation of antigen delivery and lymph node activation in nonhuman primates by saponin adjuvant saponin/monophosphoryl lipid A nanoparticle.PNAS nexus · 2024Article
- Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP.bioRxiv : the preprint server for biology · 2024Article
- Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses.Science advances · 2024Article
- A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 7 institutions in 1 country.
Ivy PhungCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.ORCID 0000-0001-7283-4766
Kristen A RodriguesKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID 0000-0002-0680-9834
Ester Marina-ZárateCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.ORCID 0000-0003-1586-404X
Laura MaiorinoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Bapi PaharTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.ORCID 0000-0003-1949-973X
Wen-Hsin LeeDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0001-9445-6671
Mariane MeloConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Amitinder KaurTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
Carolina AllersTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
Marissa FahlbergTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
Brooke F GraspergeTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
Jason P DufourTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
Faith SchiroTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
Pyone P AyeTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.ORCID 0000-0002-4764-3965
Paul G LopezCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.
Jonathan L TorresDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0003-0137-8497
Gabriel OzorowskiConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0002-9695-8138
Saman EskandarzadehConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Michael KubitzConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Erik GeorgesonConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0001-5137-4625
Bettina GroschelConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Rebecca NedellecDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Michael BickDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Katarzyna Kaczmarek MichaelsKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Hongmei GaoDepartment of Surgery, Laboratory for AIDS Vaccine Research & Development, Duke University Medical Center, Duke University, Durham, NC, 27710, USA.ORCID 0000-0002-2468-8589
Xiaoying ShenDepartment of Surgery, Laboratory for AIDS Vaccine Research & Development, Duke University Medical Center, Duke University, Durham, NC, 27710, USA.ORCID 0000-0002-8387-3952
Diane G CarnathanEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Guido SilvestriEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.ORCID 0000-0001-6602-2470
David C MontefioriDepartment of Surgery, Laboratory for AIDS Vaccine Research & Development, Duke University Medical Center, Duke University, Durham, NC, 27710, USA.ORCID 0000-0003-0856-6319
Andrew B WardConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0001-7153-3769
Lars HangartnerConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0002-3165-2058
Ronald S VeazeyTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.ORCID 0000-0002-6298-2391
Dennis R BurtonConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0001-6711-9864
William R SchiefConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0002-1120-0150
Darrell J IrvineConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA. djirvine@mit.edu.ORCID 0000-0002-8637-1405
Shane CrottyCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA. shane@lji.org.ORCID 0000-0002-6484-6262
Scripps Research Institute · USTulane University · USDuke University · USRagon Institute of MGH, MIT and Harvard · USEmory University · USInternational AIDS Vaccine Initiative · USLa Jolla Institute for Immunology · US
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MTulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MVirology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7MNIAID NIH HHS HHSN272201000004INIAID NIH HHS HHSN272201300004CNIAID NIH HHS HHSN272201700022CNIAID NIH HHS P01 AI048240NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011104NIH HHS P51 OD011132
Abstract
Adjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency virus (HIV). Antigen kinetics can change depending on the delivery method. To promote extended immunogen bioavailability and to present antigen in a multivalent form, native-HIV Env trimers are modified with short phosphoserine peptide linkers that promote tight binding to aluminum hydroxide (pSer:alum). Here we explore the use of a combined adjuvant approach that incorporates pSer:alum-mediated antigen delivery with potent adjuvants (SMNP, 3M-052) in an extensive head-to-head comparison study with conventional alum to assess germinal center (GC) and humoral immune responses. Priming with pSer:alum plus SMNP induces additive effects that enhance the magnitude and persistence of GCs, which correlate with better GC-T
Indexed as
HIV InfectionsImmunity, HumoralAdjuvants, ImmunologicAlum CompoundsAnimalsAntibodies, NeutralizingAntigensenv Gene Products, Human Immunodeficiency VirusGerminal CenterHIV AntibodiesPrimatesAdjuvants, ImmunologicAlum Compoundsaluminum sulfateAntibodies, NeutralizingAntigensenv Gene Products, Human Immunodeficiency VirusHIV Antibodies
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.